FDA-Approved Peptides List (2026): Approved vs Compounded vs Research-Only

Yes, some peptides are FDA-approved, and you probably know several of them: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro) and liraglutide (Saxenda) are all peptide drugs approved through the normal FDA process^[3][4][5][6]. A 2021 review counted more than 80 peptide drugs that have reached the market since insulin^[1]. What is not FDA-approved is the group of wellness peptides that dominates social media. Six of them (BPC-157, TB-500, MOTS-c, KPV, semax and epitalon) are covered by a draft HHS enforcement policy announced October 28, 2026: HHS says it does not intend to take action against 503A pharmacies that compound them under ten conditions. The policy is not final and is not binding on HHS or the public, and it is not approval^[11][14]. Most of the rest are sold online as research chemicals, with no FDA approval and no coverage under that policy. This page sorts peptides into those three groups, using FDA's own records.

The three groups at a glance

FDA-approved peptides for weight and metabolism

These are the approved peptide drugs most relevant to weight. Each label describes the active ingredient as a peptide or an amino-acid chain: semaglutide has a “peptide backbone” produced by yeast fermentation^[4], tirzepatide “is based on the GIP sequence”^[5], and liraglutide is built on a peptide precursor engineered to be 97% homologous to human GLP-1^[6]. Approval years are the original approval dates in Drugs@FDA^[3].

Imcivree is worth singling out because it shows how specific an approval can be. Setmelanotide is “an 8 amino acid cyclic peptide analog” of alpha-MSH^[9], and it is approved only for genetically confirmed or acquired forms of obesity listed on its label, not for general weight loss^[9]. For how these drugs compare, see Saxenda's evidence and generic status and our Wegovy and Zepbound drug pages.

Approved peptides that wellness clinics also sell

Two peptides that clinics market under nicknames are in fact FDA-approved drugs, but for narrow uses:

• Tesamorelin (Egrifta). A synthetic analog of growth hormone-releasing factor, “comprised of the 44 amino acid sequence of human GRF”^[7]. It is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Its label says it “is not indicated for weight loss management as it has a weight neutral effect”^[7]. More in our tesamorelin page and the tesamorelin evidence review.
• Bremelanotide (Vyleesi), sold by clinics as PT-141. “A synthetic, cyclic heptapeptide”^[8] approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and not for postmenopausal women^[8]. Use for other purposes, including in men, is off-label. See PT-141 and the bremelanotide evidence.

A compounded version of an approved peptide is a different product from the approved drug. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed^[13][11].

Other FDA-approved peptide drugs

Peptide drugs reach well beyond weight. Reviews of the field describe approved peptides in diabetes, cancer, osteoporosis, multiple sclerosis, HIV and chronic pain^[1], and a 2022 review in Signal Transduction and Targeted Therapy surveys how chemical modification and delivery advances have kept the class growing^[2]. A sample, with label indications summarized:

Discontinued, or never approved in the US

• Sermorelin. Approved decades ago as Geref, but Drugs@FDA lists both Geref applications as discontinued^[3]. No branded sermorelin is marketed in the US today. See sermorelin and the sermorelin evidence.
• Gonadorelin. Approved as Factrel and Lutrepulse, both listed as discontinued in Drugs@FDA^[3]. See gonadorelin.
• Thymosin alpha-1 (thymalfasin). We found no US approval record in Drugs@FDA^[3]. FDA lists it among substances it reviewed for compounding and flags immunogenicity and impurity concerns^[12]. See the thymosin alpha-1 evidence.

Group 2: the six peptides under draft HHS enforcement discretion

Under a draft HHS enforcement policy announced October 28, 2026, HHS says it does not intend to take enforcement action against State-licensed 503A pharmacies, Federal facilities or licensed physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon, when ten conditions are met^[11]. Those conditions include a patient-specific prescription, a single active ingredient, tested bulk powder from an FDA-registered manufacturer, specific routes for each peptide, and adverse-event reporting to FDA^[11]. The policy is not final and is not binding on HHS or the public, and written comments are open until November 13, 2026^[14].

None of the six is FDA-approved, and the policy does not say they are safe or effective. FDA's compounding review still lists safety concerns for each, such as possible immunogenicity and, for several, little or no human safety data^[12]. The policy is interim and HHS may revisit it^[11]. Our full explainer walks through the routes and conditions. If you are comparing providers, our pages for BPC-157, TB-500, MOTS-c, KPV, semax and epitalon list every seller we confirmed sells that peptide as a single-ingredient product, show the form each one sells, and label any form the policy does not cover; blends are left off. A listing does not confirm that the pharmacy meets the policy’s other conditions, so check them yourself with the explainer’s checklist: a certificate of analysis, a single active ingredient, the label line, an allowed route, a 510(k)-cleared syringe as the only device, and a State-licensed 503A pharmacy.

Group 3: not approved and not covered

Everything else in the wellness-peptide catalog sits here. FDA reviewed many of these for compounding and published safety concerns, including CJC-1295, ipamorelin, AOD-9604, selank, melanotan II, DSIP, LL-37 and injectable GHK-Cu^[12]. Kisspeptin-10 remains in FDA's 503A Category 2, the list of substances FDA says may present significant safety risks in compounding^[12]. None of these is on the HHS Appendix A list^[11].

Products sold as “for research use only” are not drugs made for a patient under a prescription. HHS described these research-use-only peptides from foreign manufacturers as a safety risk to US patients and framed its policy as a way to move people away from them^[11]. For the legal detail, see our guide to whether peptides are legal. For the evidence behind each peptide, see the peptides A-Z evidence guide or the peptide hub.

How to check a peptide's status yourself

1. Search Drugs@FDA for the ingredient name. An approved product shows an NDA or BLA number and a marketing status^[3].
2. Read the label on DailyMed. Section 1 lists exactly what the drug is approved for; anything else is off-label.
3. If it is compounded, ask which pharmacy makes it and whether it is a State-licensed 503A pharmacy. Our pharmacy legitimacy lookup can help, and 503A pharmacy explains the term.
4. If it is one of the six, check it against the draft HHS policy’s conditions in our policy explainer.
5. If a seller says “research use only,” it is not offering you an approved or compounded drug.